Comparative Pharmacology
Head-to-head clinical analysis: CARAC versus PICATO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARAC versus PICATO.
CARAC vs PICATO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carac (fluorouracil) is a fluorinated pyrimidine antimetabolite that inhibits thymidylate synthase, thereby interfering with DNA synthesis and repair. It also incorporates into RNA, disrupting RNA processing and function.
Ingenol mebutate is a diterpene ester that induces rapid necrosis of dysplastic epidermal cells following topical application. It exerts its effects through activation of protein kinase C (PKC) isoforms, leading to mitochondrial disruption, loss of membrane integrity, and cell death. Additionally, it induces a localized inflammatory response with neutrophil infiltration.
Apply 0.5% cream twice daily for 2-4 weeks to affected area; maximum single dose 1g, not exceed 60g per course.
Apply topically once daily to each lesion for 2 consecutive days per treatment course. Maximum of 1 tube per dose. Treatment area should not exceed 25 cm².
None Documented
None Documented
Terminal elimination half-life is approximately 20 minutes for the parent drug, but the active metabolite 5-fluorouracil (5-FU) has a half-life of 8–20 minutes; due to rapid metabolism, prolonged exposure occurs with continuous infusion.
Terminal half-life is approximately 21 hours (range 13–48 hours) in patients with actinic keratosis; no significant accumulation observed with once-daily dosing.
Primarily metabolized via dihydropyrimidine dehydrogenase (DPD) in the liver; ~10% excreted unchanged in urine; remaining metabolites eliminated renally (including CO2 and urea).
Primarily biliary/fecal (approximately 80% of absorbed dose), with renal excretion accounting for <5% of the dose as metabolites.
Category C
Category C
Topical Antineoplastic
Topical Antineoplastic